During the past decade, Aggarwal and Associates Limited conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 22 clinical trials were completed, i.e. on average, 68.8% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 16 clinical trials were completed. i.e. 94.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Aggarwal and Associates Limited" #1 sponsor was "Pfizer" with 14 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Aggarwal and Associates Limited" #1 collaborator was "ICON Clinical Research" with 2 trials as a collaborator, "Veristat, Inc." with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Department of Health and Human Services" with 1 trials as a collaborator and "TIMI Study Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Aggarwal and Associates Limited" are "Diabetes Mellitus, Type 2" (3 trials), "Type 2 Diabetes Mellitus" (3 trials), "Migraine" (2 trials), "Nonalcoholic Fatty Liver Disease" (2 trials) and "Nonalcoholic Steatohepatitis" (2 trials). Many other conditions were trialed in "Aggarwal and Associates Limited" in a lesser frequency.

Most popular intervention types in "Aggarwal and Associates Limited" are "Drug" (34 trials), "Biological" (6 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Dulaglutide" (2 trials), "PF-05221304" (2 trials), "Tirzepatide" (2 trials) and "13-valent pneumococcal conjugate vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Aggarwal and Associates Limited" are 38 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Aggarwal and Associates Limited". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Aggarwal and Associates Limited, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Aggarwal and Associates Limited, 1 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".